| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
α5β1
|
|---|---|
| ln Vitro |
The application of RGD peptide (GRGDNP) TFA (50 μM) eliminated the stretch-induced activation of IKK and IL-6 mRNA expression after a 3-hour preincubation period. In unstretched HUVECs, it has minimal impact on IL-6 mRNA expression and IKK activity[2]. Complete reversal of increased FN1 expression was observed in oxygen-glucose deprivation (OGD)-treated primary hippocampal neurons, HT22 cell lines, and their sEVs after 6 hours of treatment with RGD peptide (GRGDNP) TFA (300 μg/mL) [3].
|
| References |
[1]. C D Buckley, et al. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 1999 Feb 11;397(6719):534-9.
[2]. Wei Xia, et al. Damaged brain accelerates bone healing by releasing small extracellular vesicles that target osteoprogenitors. Nat Commun. 2021 Oct 15;12(1):6043. [3]. Akitoshi Sasamoto, et al. Mechanotransduction by integrin is essential for IL-6 secretion from endothelial cells in response to uniaxial continuous stretch. Am J Physiol Cell Physiol. 2005 May;288(5):C1012-22. |
| Molecular Formula |
C25H39F3N10O12
|
|---|---|
| Molecular Weight |
728.63
|
| Related CAS # |
RGD peptide (GRGDNP);114681-65-1
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :≥ 50 mg/mL (~68.62 mM)
DMSO :≥ 50 mg/mL (~68.62 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (137.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3724 mL | 6.8622 mL | 13.7244 mL | |
| 5 mM | 0.2745 mL | 1.3724 mL | 2.7449 mL | |
| 10 mM | 0.1372 mL | 0.6862 mL | 1.3724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
